Cargando…

Effect of Double Mutation (L452R and E484Q) on the Binding Affinity of Monoclonal Antibodies (mAbs) against the RBD—A Target for Vaccine Development

The COVID-19 pandemic, caused by SARS-CoV-2, emerges as a global health problem, as the viral genome is evolving rapidly to form several variants. Advancement and progress in the development of effective vaccines and neutralizing monoclonal antibodies are promising to combat viral infections. In the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gupta, Deepali, Kumar, Mukesh, Sharma, Priyanka, Mohan, Trishala, Prakash, Amresh, Kumari, Renu, Kaur, Punit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9860914/ https://www.ncbi.nlm.nih.gov/pubmed/36679867 http://dx.doi.org/10.3390/vaccines11010023

Ejemplares similares

Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2
por: Passariello, Margherita, et al.
Publicado: (2021)

SEPPA-mAb: spatial epitope prediction of protein antigens for mAbs
por: Qiu, Tianyi, et al.
Publicado: (2023)

Mechanisms of action of monoclonal antibodies in oncology integrated in IMGT/mAb-DB
por: Manso, Taciana, et al.
Publicado: (2023)

A new approach to quantification of mAb aggregates using peptide affinity probes
por: Cheung, Crystal S. F., et al.
Publicado: (2017)

Generation of recombinant mAbs to vaccinia virus displaying high affinity and potent neutralization
por: Noy-Porat, Tal, et al.
Publicado: (2023)

Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?
por: Lindorfer, Margaret A., et al.
Publicado: (2012)

Possible Future Monoclonal Antibody (mAb)-Based Therapy against Arbovirus Infections
por: Sautto, Giuseppe, et al.
Publicado: (2013)

Quantum leap of monoclonal antibody (mAb) discovery and development in the COVID-19 era
por: Pecetta, Simone, et al.
Publicado: (2020)

Affinity maturation pathway of an anti-MPER neutralizing mAb, CAP206-CH12
por: Tumba, NL, et al.
Publicado: (2012)

Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs
por: Fusco, Marnie L., et al.
Publicado: (2015)

SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion
por: Ferreira, Isabella A T M, et al.
Publicado: (2021)

Insights into the structure and dynamics of SARS-CoV-2 spike glycoprotein double mutant L452R-E484Q
por: Ahamad, Shahzaib, et al.
Publicado: (2022)

Concentration Effects in the Interaction of Monoclonal Antibodies (mAbs) with their Immediate Environment Characterized by EPR Spectroscopy
por: Haeri, Haleh H., et al.
Publicado: (2019)

Global Impact of Monoclonal Antibodies (mAbs) in Children: A Focus on Anti-GD2
por: Larrosa, Cristina, et al.
Publicado: (2023)

Endoplasmic reticulum retention motif fused to recombinant anti-cancer monoclonal antibody (mAb) CO17-1A affects mAb expression and plant stress response
por: Song, Ilchan, et al.
Publicado: (2018)

The Different Colors of mAbs in Solution
por: Ambrogelly, Alexandre
Publicado: (2021)

Correction: Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs
por: Fusco, Marnie L., et al.
Publicado: (2015)

Preparation and Evaluation of the Fully Humanized Monoclonal Antibody GD-mAb Against Respiratory Syncytial Virus
por: Tian, Puyuan, et al.
Publicado: (2019)

Cellular tools for biosimilar mAb analysis
por: Lindemann, Carsten, et al.
Publicado: (2013)

Evolving trends in mAb production processes
por: Shukla, Abhinav A., et al.
Publicado: (2017)

State of the art in anti-cancer mAbs
por: Chiavenna, S. M., et al.
Publicado: (2017)

Study of the interactions of a novel monoclonal antibody, mAb059c, with the hPD-1 receptor
por: Liu, Jingxian, et al.
Publicado: (2019)

Identification of the O-Glycan Epitope Targeted by the Anti-Human Carcinoma Monoclonal Antibody (mAb) NEO-201
por: Tsang, Kwong Y., et al.
Publicado: (2022)

Enhancing the Immunogenicity of RBD Protein Variants through Amino Acid E484 Mutation in SARS-CoV-2
por: Zhang, Zhikai, et al.
Publicado: (2022)

Virtual screening and molecular dynamics simulation study of approved drugs as a binder to the linoleic acid binding site on spike protein of SARS-CoV-2 and double mutant (E484Q and L452R)
por: Prajapat, Manisha, et al.
Publicado: (2022)

1363. Preliminary Safety Results from a Phase 1 First in Human Study of VYD222: an Extended Half-Life Monoclonal Antibody (mAb) in Development for COVID-19 Prevention
por: Mahoney, Kathryn, et al.
Publicado: (2023)

Physicochemical effect of the N501Y, E484K/Q, K417N/T, L452R and T478K mutations on the SARS-CoV-2 spike protein RBD and its influence on agent fitness and on attributes developed by emerging variants of concern
por: Pondé, R.A.A.
Publicado: (2022)

Anti-Fas IgM monoclonal antibody (anti-Fas mAb) effect on haemophilic arthropathy (HA) synoviocytes
por: Guiducci, Serena, et al.
Publicado: (2012)

The mAB 13A4 monoclonal antibody to the mouse PROM1 protein recognizes a structural epitope
por: Matalkah, Fatimah, et al.
Publicado: (2022)

Retrospective Analysis of Vaccinated and Unvaccinated COVID-19 Patients Treated with Monoclonal Antibodies (mAb) and Their Emergent Needs (RAVEN)
por: Simeunovic, Gordana, et al.
Publicado: (2023)

Stability enhancement in a mAb and Fab coformulation
por: Zhang, Hongyu, et al.
Publicado: (2020)

Pan-sarbecovirus mAb protects from variants
por: Flemming, Alexandra
Publicado: (2021)

A mAb for the detection of the antiretroviral drug emtricitabine
por: Youngpairoj, Ae S., et al.
Publicado: (2022)

Oxidation of specific tryptophan residues inhibits high-affinity binding of cocaine and its metabolites to a humanized anticocaine mAb
por: Kirley, Terence L., et al.
Publicado: (2022)

Antibody-Mediated Neutralization of Authentic SARS-CoV-2 B.1.617 Variants Harboring L452R and T478K/E484Q
por: Wilhelm, Alexander, et al.
Publicado: (2021)

Mutations in the SARS-CoV-2 spike RBD are responsible for stronger ACE2 binding and poor anti-SARS-CoV mAbs cross-neutralization
por: Shah, Masaud, et al.
Publicado: (2020)

E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studies
por: Wang, Wei Bu, et al.
Publicado: (2021)

mAb CZP-315.D9: An Antirecombinant Cruzipain Monoclonal Antibody That Specifically Labels the Reservosomes of Trypanosoma cruzi Epimastigotes
por: Batista, Cassiano Martin, et al.
Publicado: (2014)

Evaluation of a novel monoclonal antibody mAb109 by immuno-PET/fluorescent imaging for noninvasive lung adenocarcinoma diagnosis
por: Zhu, Hua, et al.
Publicado: (2019)

Neutralizing Monoclonal Antibody, mAb 10D8, Is an Effective Detoxicant against Abrin-a Both In Vitro and In Vivo
por: Li, Zhi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i0d8tf515j7dribp8oepf31a3d